Related Experiment Video
Updated: Jan 26, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
CD5L contributes to the pathogenesis of methicillin-resistant Staphylococcus aureus-induced pneumonia
Xun Gao1, Xingxing Yan2, Qun Zhang3
1Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Key Laboratory of Diagnostic Medicine designated by the Ministry of Education, Chongqing Medical University, Chongqing, China.
Abstract:
Staphylococcus aureus is a major causative microorganism in community- and healthcare-acquired pneumonia. CD5L is an important protein in the control of immune homeostasis. In this study, we found that patients with S. aureus pneumonia displayed increased levels of circulating CD5L. Likewise, mice with S. aureus pneumonia had elevated CD5L levels in the lungs. Anti-CD5L antibody protected mice from lethal pneumonia induced by methicillin-resistant S. aureus. The survival benefit obtained with antibody against CD5L was associated with an improvement of bacterial clearance and a reduction of pulmonary inflammatory cytokines and chemokines. Conversely, co-injection of recombinant CD5L and S. aureus markedly increased the lethality of S. aureus pneumonia. These findings suggest that CD5L contributed to the immunopathology of S. aureus pneumonia.
Insights
This study reveals that CD5L protein levels increase during Staphylococcus aureus pneumonia. Targeting CD5L with an antibody improved survival by reducing inflammation and bacterial load in mice.
Area of Science:
- Immunology
- Microbiology
- Pulmonology
Background:
- Staphylococcus aureus is a primary cause of community- and healthcare-acquired pneumonia.
- CD5L is a key regulator of immune homeostasis.
Purpose of the Study:
- To investigate the role of CD5L in Staphylococcus aureus pneumonia.
- To evaluate the therapeutic potential of targeting CD5L in S. aureus pneumonia.
Main Methods:
- Measurement of CD5L levels in patients and mice with S. aureus pneumonia.
- Administration of anti-CD5L antibody or recombinant CD5L in a mouse model.
- Assessment of bacterial clearance, survival rates, and pulmonary inflammatory markers.
Main Results:
- Elevated circulating and lung CD5L levels were observed in S. aureus pneumonia.
- Anti-CD5L antibody treatment enhanced survival, bacterial clearance, and reduced pulmonary inflammation.
- Recombinant CD5L exacerbated S. aureus pneumonia lethality.
Conclusions:
- CD5L plays a significant role in the immunopathology of S. aureus pneumonia.
- Targeting CD5L represents a potential therapeutic strategy for S. aureus pneumonia.
More Related Videos
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Binet's Contribution to Measures of Intelligence
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...

